Kinetics of interaction between 3-hydroxyphthaloyl-β-lactoglobulin and CD4 molecules

Biologicals

Volumn 27, Issue 1, 1999, Pages 29-34

  Zeder Lutz, G ^a   Neurath, A R ^b   Van Regenmortel, M H V ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID ANHYDRIDE; CD4 ANTIGEN; LACTOGLOBULIN;

ARTICLE; ASSOCIATION; BINDING AFFINITY; BIOSENSOR; CONTROLLED STUDY; DEVICE; DISSOCIATION; KINETICS; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

EID: 0032780214     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1999.0166     Document Type: Article

References (15)

1. Neurath AR, Jiang S, Strick N. Bovine β-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nature Med. 2: 1996; 230-234.
2. Jiang S, Li Y-Y, Lin K. Virucidal and antibacterial activities of 3-hydroxyphthaloyl-β-lactoglobulin. Vaccines 97. Molecular Approaches to the Control of Infectious Diseases. 1997: Cold Spring Harbor Laboratory Press, Cold Spring Harbor. p. 327-330.
3. Neurath AR, Strick N, Li Y-Y. 3-Hydroxyphthaloyl-β-lactoglobulin: III. Antiviral activity against herpesviruses. Antivir Chem Chemother. 9:1998; 177-184.
4. Kokuba H, Aurelian L, Neurath AR. 3Hydroxyphthaloyl-β-lactoglobulin: IV. Antiviral activity in the mouse model of genital herpesvirus infection. Antivir Chem Chemother. 9:1998; 353-357.
5. Van Cott TC, Bethke FR, Polonis AR. Dissociation rate of antibody-gp120 interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:1994; 449-458.
6. Neurath AR, Debnath AK, Strick N. Blocking of CD4 cell receptors for human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. J Mol Recognit. 8:1995; 304-316.
7. Neurath AR, Debnath AK, Strick N. 3-Hydroxyphthaloyl-β-lactoglobulin: I. Optimization of production and comparison with other compounds considered for chemoprophylaxis of mucosally transmitted human immunodeficiency virus type 1. Antivir Chem. Chemother. 8:1997; 131-139.
8. Glaser RW. Antigen-antibody binding and mass-transport by convection and diffusion to surface: A two-dimensional computer model of binding and dissociation kinetics. Anal Biochem. 213:1993; 152-161.
9. Johnsson B, Löfas S, Lindqvist G. Immobilization of proteins to a carboxymethyldextran modified gold surface for biospecific interaction analysis in surface plasmon resonance. Anal Biochem. 198:1991; 268-277.
10. Christensen LL. Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Anal Biochem. 249:1997; 153-164.
11. Richalet-Sécordel PM, Rauffer-Bruyère N, Christensen LLH. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal Biochem. 249:1997; 165-173.
12. Karlsson R, Fält A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Methods. 200:1997; 121-133.
13. O'Shannessy DJ, Winzor DJ. Interpretation of deviations from pseudo-first order kinetic behavior in the characterization of ligand binding by biosensor technology. Anal Biochem. 236:1996; 275-283.
14. Brown AM, Pfeffer PE, Kumosinski TF. Accessibility and mobility of lysine residues in β-lactoglobulin. Biochemistry. 27:1988; 5601-5610.
15. Berkhout B, Derksen GC, Klaver B. Structural and functional analysis of negatively charged milk proteins with anti-HIV activity. AIDS Res Hum Retroviruses. 13:1997; 1101-1107.